CeriBell (NASDAQ:CBLL) Stock: Insider Raymond Woo Sells 4,887 Shares

CeriBell, Inc. (NASDAQ:CBLL) CTO Raymond Woo sold 4,887 shares of the company’s stock in a transaction that occurred on Monday, November 2nd. The shares were sold at an average price of $26.96, for a total transaction of $131,753.52. Following the completion of the sale, the chief technology officer owned 203,118 shares of the company’s stock, valued at approximately $5,476,061.28. This trade represents a 2.35% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link.

Raymond Woo also recently made the following trade(s):

• On Thursday, October 1st, Raymond Woo sold 4,887 shares of CeriBell stock. The stock was sold at an average price of $24.38, for a total transaction of $119,145.06.
• On Tuesday, September 8th, Raymond Woo sold 4,887 shares of CeriBell stock. The stock was sold at an average price of $24.33, for a total transaction of $118,900.71.
• On Friday, August 21st, Raymond Woo sold 1,979 shares of CeriBell stock. The stock was sold at an average price of $24.02, for a total transaction of $47,535.58.

CeriBell Price Performance

Shares of NASDAQ:CBLL opened at $26.01 on Friday. The company’s fifty day moving average is $25.18 and its two-hundred day moving average is $20.89. The company has a quick ratio of 8.79, a current ratio of 8.18 and a debt-to-equity ratio of 0.17. CeriBell, Inc. has a 12-month low of $11.27 and a 12-month high of $28.89. The company has a market cap of $1.01 billion, a P/E ratio of -13.41 and a beta of 0.86.

CeriBell (NASDAQ:CBLL) last issued its earnings results on Tuesday, November 3rd. The company reported ($0.55) EPS for the quarter, missing the consensus estimate of ($0.51) by ($0.04). CeriBell had a negative return on equity of 52.59% and a negative net margin of 67.96%. The business had revenue of $29.34 million during the quarter, compared to analyst estimates of $29.18 million. Equities analysts expect that CeriBell, Inc. will post -1.96 earnings per share for the current fiscal year.

Hedge Funds Weigh In On CeriBell

Hedge funds have recently modified their holdings of the stock. Lisanti Capital Growth LLC purchased a new stake in shares of CeriBell during the third quarter worth $4,466,000. Squarepoint Ops LLC acquired a new stake in CeriBell during the second quarter valued at $638,000. Wellington Management Group LLP grew its stake in CeriBell by 5.5% in the second quarter. Wellington Management Group LLP now owns 87,698 shares of the company’s stock valued at $1,706,000 after purchasing an additional 4,572 shares in the last quarter. Formula Growth Ltd. purchased a new position in CeriBell in the second quarter valued at about $603,000. Finally, Bank of America Corp DE purchased a new position in CeriBell in the second quarter valued at about $4,619,000.

Wall Street Analyst Weigh In

A number of brokerages have commented on CBLL. Canaccord Genuity Group raised their price objective on CeriBell from $26.00 to $33.00 and gave the stock a “buy” rating in a research report on Wednesday. Weiss Ratings upgraded CeriBell from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, October 16th. Barclays raised shares of CeriBell to a “neutral” rating in a research report on Tuesday, August 18th. Raymond James Financial restated a “strong-buy” rating and set a $29.00 price target on shares of CeriBell in a report on Thursday, September 3rd. Finally, TD Cowen raised their price target on shares of CeriBell from $29.00 to $33.00 and gave the stock a “buy” rating in a report on Friday, October 2nd. One equities research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $31.25.

CeriBell Company Profile

CeriBell, Inc is a medical technology company that develops artificial intelligence-enabled neurological diagnostic products. Its technology is designed to help healthcare professionals rapidly identify and monitor seizures, including nonconvulsive seizures that may be difficult to recognize through a standard clinical examination.

The company’s primary product is the Ceribell Rapid Response EEG system, a portable electroencephalography platform that combines a wireless EEG recorder, a simplified disposable headband, and software-based analysis tools.